Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)

The aim of this COST Action is to join highly-qualified research teams working in disciplines around the field of medicinal chemistry, into a novel network devoted to the multi-target issue in drug discovery. The choice of this theme is related to its marked multidisciplinary character, which can ensure a strong interaction among all COST Action participants. Currently, an important and emerging issue in modern drug discovery is to design novel or identify existing bioactive compounds, endowed with the capability to interact selectively with two or more macromolecular targets, exerting their effects against certain therapeutic goals in a synergic fashion. This leading concept stimulated this COST Action focusing on novel ligands able to recognize selected multiple targets, to promote closer scientific links among European research groups involved in medicinal chemistry field at both academic and industrial level. The research competencies of the network will span around medicinal chemistry, from synthetic chemistry, natural products and biophysics to theoretical chemistry, molecular modelling and biological screening.

 

ACTION DETAILS

Memorandum of Understanding (MoU): 067/15 – Download Here

Committee of Senior Officials Approval date: 30/10/2015

Start of Action: 18/04/2016

End of Action: 17/04/2020

Total number of COST Countries having accepted the MoU